<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PHENDIMETRAZINE TARTRATE- phendimetrazine tartrateÂ tabletÂ </strong><br>Blenheim Pharmacal, Inc.<br></p></div>
<h1>PHENDIMETRAZINE
 <br><br>
TARTRATE TABLETS,
 <br><br>
USP 35 mg, CIII
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First">Rx Only</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY:
</span></h1>
<p class="First">Phendimetrazine tartrate is a sympathomimetic amine with pharmacological activity similar to the prototype drugs of this class used in <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. <span class="product-label-link" type="condition" conceptid="4052861" conceptname="Tachyphylaxis">Tachyphylaxis</span> and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.</p>
<p>Drugs of this class used in <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> are commonly known as â€œanorecticsâ€? or â€œanorexigenicsâ€?. It has not been established, however, that the action of such drugs in treating <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> is primarily one of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">appetite suppression</span>. Other central nervous system actions or metabolic effects, may be involved for example.</p>
<p>Adult obese subjects instructed in dietary management and treated with <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> drugs, lose more weight on the average than those treated with placebo and diet, as determined in relatively short term clinical trials.</p>
<p>The magnitude of increased <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. The rate of <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The possible origin of the increased <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> due to the various drug effects is not established. The amount of <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> associated with the use of an <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> drug varies from trial to trial, and the increased <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> appears to be related in part to variables other than the drug prescribed, such as the physician investigator, the population treated, and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.</p>
<p>The natural history of <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> is measured in years, whereas the studies cited are restricted to a few weeks duration; thus, the total impact of drug-induced <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> over that of diet alone must be considered clinically limited.</p>
<p>The major route of elimination is via the kidneys where most of the drug and metabolites are excreted. Some of the drug is metabolized to phendimetrazine and phendimetrazine-N-oxide. The average half-life of elimination when studied under controlled conditions is about 3.7 hours for both the extended-release and immediate release forms. The absorption half-life of the drug from the immediate release 35 mg phendimetrazine tablets is appreciably more rapid than the absorption rate of the drug from the extended-release formulation.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE:
</span></h1>
<p class="First">Phendimetrazine tartrate is indicated in the management of exogenous <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI) of 30 kg/m
       
 
  <span class="Sup">2</span> or higher who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Below is a chart of Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Index (BMI) based on various heights and weights. BMI is calculated by taking the patientâ€™s weight, in kilograms (kg), divided by the patientâ€™s height, in meters (m), squared. Metric conversions are as follows: pounds Ã· 2.2 = kg; inches x 0.0254 = meters.
      

 </p>
<table frame="void" width="590">
<caption><span> BODY <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">MASS</span> INDEX (BMI), kg/m
        
  
   <span class="Sup">2</span> Height (feet, inches)
       
 
  </span></caption>
<thead><tr class="First Last">
<td align="center" valign="middle"> Weight(pounds)</td>
<td class="Botrule" align="center" valign="middle"> 5â€™0â€?</td>
<td align="center" valign="middle"> 5â€™3â€?</td>
<td align="center" valign="middle"> 5â€™6â€?</td>
<td align="center" valign="middle"> 5â€™9â€?</td>
<td align="center" valign="middle"> 6â€™0â€?</td>
<td align="center" valign="middle"> 6â€™3â€?</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Rrule" align="center" valign="middle">140</td>
<td class="LruleRruleToprule" align="center" valign="middle">27</td>
<td class="BotruleLrule" align="center" valign="middle">25</td>
<td align="center" valign="middle">23</td>
<td align="center" valign="middle">21</td>
<td align="center" valign="middle">19</td>
<td align="center" valign="middle">18</td>
</tr>
<tr>
<td class="Rrule" align="center" valign="middle">150</td>
<td class="BotruleLruleRrule" align="center" valign="middle">29</td>
<td class="LruleRruleToprule" align="center" valign="middle">27</td>
<td class="Lrule" align="center" valign="middle">24</td>
<td align="center" valign="middle">22</td>
<td align="center" valign="middle">20</td>
<td align="center" valign="middle">19</td>
</tr>
<tr>
<td align="center" valign="middle">160</td>
<td class="RruleToprule" align="center" valign="middle">31</td>
<td class="BotruleLruleRrule" align="center" valign="middle">28</td>
<td class="BotruleLrule" align="center" valign="middle">26</td>
<td align="center" valign="middle">24</td>
<td align="center" valign="middle">22</td>
<td align="center" valign="middle">20</td>
</tr>
<tr>
<td align="center" valign="middle">170</td>
<td align="center" valign="middle">33</td>
<td class="RruleToprule" align="center" valign="middle">30</td>
<td class="LruleRruleToprule" align="center" valign="middle">28</td>
<td class="BotruleLrule" align="center" valign="middle">25</td>
<td align="center" valign="middle">23</td>
<td align="center" valign="middle">21</td>
</tr>
<tr>
<td align="center" valign="middle">180</td>
<td align="center" valign="middle">35</td>
<td class="Rrule" align="center" valign="middle">32</td>
<td class="BotruleLruleRrule" align="center" valign="middle">29</td>
<td class="LruleRruleToprule" align="center" valign="middle">27</td>
<td class="Lrule" align="center" valign="middle">25</td>
<td align="center" valign="middle">23</td>
</tr>
<tr>
<td align="center" valign="middle">190</td>
<td align="center" valign="middle">37</td>
<td align="center" valign="middle">34</td>
<td class="RruleToprule" align="center" valign="middle">31</td>
<td class="BotruleLruleRrule" align="center" valign="middle">28</td>
<td class="BotruleLrule" align="center" valign="middle">26</td>
<td align="center" valign="middle">24</td>
</tr>
<tr>
<td align="center" valign="middle">200</td>
<td align="center" valign="middle">39</td>
<td align="center" valign="middle">36</td>
<td align="center" valign="middle">32</td>
<td class="RruleToprule" align="center" valign="middle">30</td>
<td class="LruleRruleToprule" align="center" valign="middle">27</td>
<td class="Lrule" align="center" valign="middle">25</td>
</tr>
<tr>
<td align="center" valign="middle">210</td>
<td align="center" valign="middle">41</td>
<td align="center" valign="middle">37</td>
<td align="center" valign="middle">34</td>
<td class="Rrule" align="center" valign="middle">31</td>
<td class="BotruleLruleRrule" align="center" valign="middle">29</td>
<td class="BotruleLrule" align="center" valign="middle">26</td>
</tr>
<tr>
<td align="center" valign="middle">220</td>
<td align="center" valign="middle">43</td>
<td align="center" valign="middle">39</td>
<td align="center" valign="middle">36</td>
<td align="center" valign="middle">33</td>
<td class="RruleToprule" align="center" valign="middle">30</td>
<td class="LruleRruleToprule" align="center" valign="middle">28</td>
</tr>
<tr>
<td align="center" valign="middle">230</td>
<td align="center" valign="middle">45</td>
<td align="center" valign="middle">41</td>
<td align="center" valign="middle">37</td>
<td align="center" valign="middle">34</td>
<td class="Rrule" align="center" valign="middle">31</td>
<td class="BotruleLruleRrule" align="center" valign="middle">29</td>
</tr>
<tr>
<td align="center" valign="middle">240</td>
<td align="center" valign="middle">47</td>
<td align="center" valign="middle">43</td>
<td align="center" valign="middle">39</td>
<td align="center" valign="middle">36</td>
<td align="center" valign="middle">33</td>
<td class="Toprule" align="center" valign="middle">30</td>
</tr>
<tr class="Last">
<td align="center" valign="middle">250</td>
<td align="center" valign="middle">49</td>
<td align="center" valign="middle">44</td>
<td align="center" valign="middle">40</td>
<td align="center" valign="middle">37</td>
<td align="center" valign="middle">34</td>
<td align="center" valign="middle">31</td>
</tr>
</tbody>
</table>
<p>Phendimetrazine tartrate is indicated for use as monotherapy only.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS:
</span></h1>
<p class="First">Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or idiosyncratic reactions to sympathomimetics.</p>
<p>Advanced <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">arteriosclerosis</span>, symptomatic cardiovascular disease, moderate and severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, and <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
<p>Highly nervous or <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> patients.</p>
<p>Patients with a history of drug abuse.</p>
<p>Patients taking other CNS stimulants, including monoamine oxidase inhibitors.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1><span class="Bold">WARNINGS:
</span></h1>
<p class="First"><span class="Bold">Phendimetrazine tartrate should not be used in combination with other <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> agents, including prescribed drugs, over-the-counter preparations and herbal products.</span></p>
<p>In a case-control epidemiological study, the use of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> agents, including phendimetrazine tartrate, was associated with an increased risk of developing <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>, a rare, but often fatal disorder. The use of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> agents for longer than three months was associated with a 23-fold increase in the risk of developing <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>. Increased risk of <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> with repeated courses of therapy cannot be excluded.</p>
<p>The onset or aggravation of <span class="product-label-link" type="condition" conceptid="4263848" conceptname="Dyspnea on exertion">exertional dyspnea</span>, or unexplained symptoms of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or lower extremity <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> suggest the possibility of occurrence of <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>. Under these circumstances, phendimetrazine tartrate should be immediately discontinued, and the patient should be evaluated for the possible presence of <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">Valvular heart disease</span> associated with the use of some <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> agents such as fenfluramine and dexfenfluramine has been reported. Possible contributing factors include use for extended periods of time, higher than recommended dose, and/or use in combination with other <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> drugs. However, no cases of this valvulopathy have been reported when phendimetrazine tartrate has been used alone.</span></p>
<p>The potential risk of possible serious adverse effects such as <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">valvular heart disease</span> and <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> should be assessed carefully against the potential benefit of <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. Baseline cardiac evaluation should be considered to detect pre-existing <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">valvular heart diseases</span> or <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> prior to initiation of phendimetrazine treatment. Phendimetrazine tartrate is not recommended in patients with known <span class="product-label-link" type="condition" conceptid="316822" conceptname="Heart murmur">heart murmur</span> or <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">valvular heart disease</span>. Echocardiogram during and after treatment could be useful for detecting any valvular disorders which may occur. To limit unwarranted exposure and risks, treatment with phendimetrazine tartrate should be continued only if the patient has satisfactory <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> within the first 4 weeks of treatment (i.e., <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> of at least 4 pounds, or as determined by the physician and patient).</p>
<p>Tolerance to the <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> effect of phendimetrazine develops within a few weeks. When this occurs, its use should be discontinued; the maximum recommended dose should not be exceeded.</p>
<p>Use of phendimetrazine tartrate within 14 days following the administration of monoamine oxidase inhibitors may result in a <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>.</p>
<p>Abrupt cessation of administration following prolonged high dosage results in extreme <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Because of the effect on the central nervous system, phendimetrazine tartrate may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.</p>
<p>Phendimetrazine tartrate is not recommended for patients who used any <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> agents within the prior year.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1><span class="Bold">PRECAUTIONS:
</span></h1>
<p class="First">Caution is to be exercised in prescribing phendimetrazine for patients with even mild <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p>Insulin requirements in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus may be altered in association with the use of phendimetrazine tartrate and the concomitant dietary regimen.</p>
<p>Phendimetrazine tartrate may decrease the hypotensive effect of guanethidine. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.</p>
<p>Only yellow tablet contains FD&amp;C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>) in certain susceptible persons. Although the overall incidence of FD&amp;C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<div class="Section">
<a name="section-6.1"></a><p></p>
<h2><span class="Bold">Drug Interactions:
</span></h2>
<p class="First">Efficacy of phendimetrazine tartrate with other <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> agents has not been studied and the combined use may have the potential for serious cardiac problems.</p>
</div>
<div class="Section">
<a name="section-6.2"></a><p></p>
<h2><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:
</span></h2>
<p class="First">Studies with Phendimetrazine Tartrate have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.</p>
</div>
<div class="Section">
<a name="section-6.3"></a><p></p>
<h2><span class="Bold"><span class="Italics">Pregnancy: Pregnancy Category C:
</span></span></h2>
<p class="First">Animal reproduction studies have not been conducted with phendimetrazine tartrate. It is also not known whether phendimetrazine tartrate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.</p>
<p><span class="Bold">Usage in Pregnancy:</span></p>
<p>Safe use in pregnancy has not been established. Until more information is available, phendimetrazine tartrate should not be taken by women who are or may become pregnant unless, in the opinion of the physician, the potential benefits outweigh the possible hazards.</p>
</div>
<div class="Section">
<a name="section-6.4"></a><p></p>
<h2><span class="Bold">Nursing Mothers:
</span></h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, phendimetrazine tartrate should not be taken by women who are nursing unless, in the opinion of the physician, the potential benefits outweigh the possible hazards.</p>
</div>
<div class="Section">
<a name="section-6.5"></a><p></p>
<h2><span class="Bold">Pediatric Use:
</span></h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS:
</span></h1>
<p class="First"><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, elevated blood pressure, ischemic events.
      

 </p>
<p><span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">Valvular heart disease</span> associated with the use of some <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> agents such as fenfluramine and dexfenfluramine, both independently and especially when used in combination with other <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> drugs, have been reported. However, no case of this valvulopathy has been reported when phendimetrazine tartrate has been used alone.</p>
<div class="Section">
<a name="section-7.1"></a><p></p>
<h2><span class="Bold">Central Nervous System:
</span></h2>
<p class="First">Overstimulation, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic state</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span>.</p>
<p><span class="Bold">Gastrointestinal:</span></p>
<p>Dryness of the mouth, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>.</p>
<p><span class="Bold">Genitourinary:</span></p>
<p><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, changes in libido.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-8"></a><p></p>
<h1><span class="Bold">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>:
</span></h1>
<p class="First"><span class="Bold">Controlled Substance:</span></p>
<p>Phendimetrazine tartrate tablets are a Schedule lll controlled substance.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>:</span></p>
<p>Phendimetrazine tartrate is related chemically and pharmacologically to the amphetamines. Amphetamines and related stimulant drugs have been extensively abused, and the possibility of abuse of phendimetrazine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. Abuse of amphetamines and related drugs may be associated with intense psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and severe social dysfunction. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; changes are also noted on the sleep EEG. Manifestations of chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> with <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> drugs include severe dermatoses, marked <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> and <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>. The most severe manifestation of chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxications</span> is <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, often clinically indistinguishable from <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1><span class="Bold">OVERDOSAGE:
</span></h1>
<p class="First">Acute overdosage with phendimetrazine tartrate may manifest itself by the following signs and symptoms: unusual <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, belligerence, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, and panic states. <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> usually follow the central stimulation. Cardiovascular effects include <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>. <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal symptoms</span> include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>. <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span> may result in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>The management of overdosage is largely symptomatic. It includes sedation with a barbiturate. If <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> is marked, the use of a nitrate or rapid-acting alpha receptor-blocking agent should be considered. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations for its use.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION:
</span></h1>
<p class="First"><span class="Bold">Usual Adult Dosage:</span> 1 tablet (35 mg) twice a day or three times a day one hour before meals.
      

 </p>
<p>Dosage should be individualized to obtain an adequate response with the lowest effective dosage. In some cases, Â½ tablet (17.5 mg) per dose may be adequate. Dosage should not exceed 2 tablets three times a day.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED:
</span></h1>
<p class="First"><span class="Bold">Phendimetrazine Tartrate Tablets, USP 35 mg </span>are available as
      

 </p>
<p>White, round, biconvex tablets debossed â€œKâ€? above bisect â€œ45â€? on one side and plain on the other side.</p>
<p>Bottles of 30 NDC 10702-045-03</p>
<p>Bottles of 100 NDC 10702-045-01</p>
<p>Bottles of 1000 NDC 10702-045-10</p>
<p>Yellow, round, biconvex tablets debossed â€œKâ€? above bisect â€œ77â€? on one side and plain on the other side.</p>
<p>Bottles of 30 NDC 10702-077-03</p>
<p>Bottles of 100 NDC 10702-077-01</p>
<p>Bottles of 1000 NDC 10702-077-10</p>
<p>Blue, round, biconvex tablets debossed â€œKâ€? above bisect â€œ78â€? on one side and plain on the other side.</p>
<p>Bottles of 30 NDC 10702-078-03</p>
<p>Bottles of 100 NDC 10702-078-01</p>
<p>Bottles of 1000 NDC 10702-078-10</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="id_link_111ca478-bfe8-1c46-e054-00144ff88e88"></a><a name="section-12"></a><p></p>
<p class="First">Store at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted between 15Â° to 30Â°C (59Â° to 86Â°F) [See USP Controlled Room Temperature].</p>
<p><span class="Bold">DEA Order Form Required.</span></p>
<p>Manufactured by:</p>
<p>KVK-TECH, INC.</p>
<p>110 Terry Drive Suite 200</p>
<p>Newtown, PA 18940-1850</p>
<p>Item ID # 006080/05                     09/10</p>
<p>Manufacturerâ€™s Code: 10702</p>
<p></p>
<p><img alt="KVK - Tech" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=112cbc20-15ab-5ac1-e054-00144ff8d46c&amp;name=3e594fab-figure-02.jpg"></p>
<p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="id_link_111c9156-2820-1694-e054-00144ff8d46c"></a><a name="section-13"></a><p></p>
<h1><span class="Bold">DESCRIPTION: </span></h1>
<p class="First">Phendimetrazine tartrate, as the dextro isomer, has the chemical name of (2S,3S)-3,4-Dimethyl-2-phenylmorpholine L-(+)- tartrate (1:1).</p>
<p>The structural formula is:</p>
<p><img alt="Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=112cbc20-15ab-5ac1-e054-00144ff8d46c&amp;name=3e594fab-figure-01.jpg"></p>
<p></p>
<p>Phendimetrazine tartrate is a white, odorless crystalline powder. It is freely soluble in water; sparingly soluble in warm alcohol, insoluble in chloroform, acetone, ether and benzene.</p>
<p>Each white tablet, for oral administration, contains 35 mg of phendimetrazine tartrate. In addition, the following inactive ingredients are present: Colloidal Silicon Dioxide, Lactose Monohydrate, Magnesium Stearate, Microcrystalline Cellulose 102 and Sodium Starch Glycolate. The yellow tablet also contains  FD&amp;C Yellow # 5 Aluminum Lake (15-17%). The blue tablet also contains FD&amp;C Blue # 1 Aluminum Lake (11-13%).</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="id_link_111c9156-2827-1694-e054-00144ff8d46c"></a><a name="section-14"></a><p></p>
<h1><span class="Bold">Principal Display Panel</span></h1>
<p class="First"><span class="Bold">Phendimetrazine Tartrate Tablets, USP 35mg CIII</span></p>
<p><span class="Bold">30 Tablets</span></p>
<p><span class="Bold">NDC 10544-041-30</span></p>
<p></p>
<p><img alt="35mg 30ct" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=112cbc20-15ab-5ac1-e054-00144ff8d46c&amp;name=LABEL_PHENDIMETRAZINE%20TARTRATE%20TABS%2035MG_BPI(10544-041-30)_KVK-TECH(10702-077-10)_REV1.jpg"></p>
<p></p>
<p></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PHENDIMETRAZINE TARTRATEÂ 		
					</strong><br><span class="contentTableReg">phendimetrazine tartrate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10544-041(NDC:10702-077)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PHENDIMETRAZINE TARTRATE</strong> (PHENDIMETRAZINE) </td>
<td class="formItem">PHENDIMETRAZINE TARTRATE</td>
<td class="formItem">35Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">K;45</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10544-041-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">03/15/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091042</td>
<td class="formItem">03/15/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Blenheim Pharmacal, Inc.
							(171434587)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Blenheim Pharmacal, Inc. (171434587)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Blenheim Pharmacal, Inc.</td>
<td class="formItem"></td>
<td class="formItem">171434587</td>
<td class="formItem">repack(10544-041)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>112cbc20-15ac-5ac1-e054-00144ff8d46c</div>
<div>Set id: 112cbc20-15ab-5ac1-e054-00144ff8d46c</div>
<div>Version: 2</div>
<div>Effective Time: 20150312</div>
</div>
</div>Â <div class="DistributorName">Blenheim Pharmacal, Inc.</div></p>
</body></html>
